Investigation of the efficacy of siRNA mediated KRAS gene silencing in pancreatic cancer therapy-

Basit Öğe Kaydı
dc.authoridBUDAK YILDIRAN, Fatma Azize/0000-0001-7031-6834
dc.contributor.authorKucukekmekci, Busra
dc.contributor.authorYildiran, Fatma Azize Budak
dc.date.accessioned2025-01-21T16:42:12Z
dc.date.available2025-01-21T16:42:12Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAim. Pancreatic carcinoma is an aggressive cancer that progresses without many symptoms. The difficulty of early diagnosis and an inadequate response to traditional treatments also cause the survival rate of pancreatic cancer to be low. Current research is focusing on methods of diagnosis and treatment, such as gene therapy, to increase survival rates. Small interfering ribonucleic acid (siRNA) has emerged as a promising advanced therapeutic strategy for cancer treatment. This study sought to silence the KRAS gene in the human pancreatic carcinoma cell line using a complex of small interfering ribonucleic acid (siRNA) and gold nanoparticles (AuNP). Methods. In this study, 25 nM siRNA and gold nanoparticles at 0.5 mg/ml, 0.25 mg/ml, and 0.125 mg/ml concentrations were used to silence the KRAS gene in the CAPAN-1 cell line. Real-time PCR analysis, agarose gel electrophoresis, and double staining were carried out, and xCelligence real-time cell analysis (RTCA) was used to measure proliferation. Results. The PCR analysis revealed crossing point (CP) values of actin beta (ACTB) ranging from 33.04 to 35.98, which was in the expected range for all samples. The interaction between the gold nanoparticle/siRNA complex in the double staining analysis revealed that the most effective concentration of gold nanoparticle was 0.125 mg/ml. The WST-1 technique showed that siRNA/AuPEI cells in application groups had a viability rate of over 90%, indicating no toxicity or side effects. The xCELLigence RTCA (R) showed that at hour 72, there was a significant difference in proliferation in the 0.5 mg/mL PEI/AuNP-siRNA, 0.25 mg/mL PEI/AuNP-siRNA, and 0.125 mg/mL PEI/AuNP-siRNA application groups compared to the control and siRNA groups (p < 0.05). By hour 96, all three groups were statistically different from the control and siRNA groups in terms of proliferation (p < 0.05). Conclusions. The results of this analysis suggest that the AuPEI/siRNA complex can be effectively used to silence the target gene, but more studies are needed to verify these results.
dc.description.sponsorshipKimath;rimath;kkale University Scientific Research Projects (BAP) [2021/124]
dc.description.sponsorshipThis article was supported by K & imath;r & imath;kkale University Scientific Research Projects (BAP) unit within the scope of project no. 2021/124. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.identifier.doi10.7717/peerj.18214
dc.identifier.issn2167-8359
dc.identifier.pmid39553720
dc.identifier.scopus2-s2.0-85209904887
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.7717/peerj.18214
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25013
dc.identifier.volume12
dc.identifier.wosWOS:001356728900002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPeerj Inc
dc.relation.ispartofPeerj
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectsiRNA; Capan-1; KRAS; Real-Time PCR; AuNP
dc.titleInvestigation of the efficacy of siRNA mediated KRAS gene silencing in pancreatic cancer therapy-
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu